Seelos Therapeutics Analysis
Seelos Therapeutics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Seelos Therapeutics otc analysis is to determine its intrinsic value, which is an estimate of what Seelos Therapeutics is worth, separate from its market price. There are two main types of Seelos Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Seelos Therapeutics otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Seelos |
Seelos OTC Stock Analysis Notes
The company recorded earning per share (EPS) of 351.04. Seelos Therapeutics last dividend was issued on the 24th of January 2019. The entity had 1:16 split on the 27th of September 2024. Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York. Seelos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.The quote for Seelos Therapeutics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Seelos Therapeutics contact the company at 646 293 2100 or learn more at https://seelostherapeutics.com.Seelos Therapeutics Investment Alerts
| Seelos Therapeutics is not yet fully synchronised with the market data | |
| Seelos Therapeutics has some characteristics of a very speculative penny stock | |
| Seelos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.2 M. Net Loss for the year was (37.88 M) with loss before overhead, payroll, taxes, and interest of (46.65 M). | |
| Seelos Therapeutics currently holds about 41.25 M in cash with (23.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. |
Seelos Therapeutics Upcoming and Recent Events
Earnings reports are used by Seelos Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Seelos Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 743.68 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Seelos Therapeutics's market, we take the total number of its shares issued and multiply it by Seelos Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Seelos Profitablity
Seelos Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Seelos Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Seelos Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Seelos Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Seelos Therapeutics' profitability requires more research than a typical breakdown of Seelos Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 2.03 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is normal as compared to the sector avarege. Similarly, it shows Operating Margin (OM) of (8.35) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $8.35. Seelos Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Seelos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Seelos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Seelos Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mehra Raj over three months ago Acquisition by Mehra Raj of 2282262 shares of Seelos Therapeutics at 1.08 subject to Rule 16b-3 | ||
Mehra Raj over three months ago Acquisition by Mehra Raj of 75757 shares of Seelos Therapeutics at 1.32 subject to Rule 16b-3 | ||
O'connor Daniel J. over three months ago Acquisition by Oconnor Daniel J. of 50000 shares of Seelos Therapeutics subject to Rule 16b-3 | ||
Lian Brian over six months ago Insider Trading | ||
Smith Sandford D over a year ago Purchase by Smith Sandford D of 18200 shares of Seelos Therapeutics | ||
Richard Pascoe over a year ago Acquisition by Richard Pascoe of 1666 shares of Seelos Therapeutics subject to Rule 16b-3 |
Seelos Therapeutics Outstanding Bonds
Seelos Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Seelos Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Seelos bonds can be classified according to their maturity, which is the date when Seelos Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Seelos Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in income. Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Seelos OTC Stock
If you are still planning to invest in Seelos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seelos Therapeutics' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |